Nikolay Dorokhov

Nikolay Dorokhov

Auto-generated profile, based on publicly available information

Nikolay Dorokhov

Department of Faculty Therapy No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2026 in Life
Verified
Journal Article
Open access
PDF file
TSTatiana Safronova
Tatiana Safronova
SMSofia Eduardovna Mukhanova
Sofia Eduardovna Mukhanova
ABAnna E. Bragina
Anna E. Bragina
ATAida I. Tarzimanova
Aida I. Tarzimanova
AIAlexander Ivannikov
Alexander Ivannikov
VPValery I. Podzolkov
Valery I. Podzolkov
Background: Arterial hypertension (HTN) is associated with accelerated vascular aging, cerebral microvascular injury, and cognitive decline. Anti-NR2/GluN2 (NR2) antibodies may be related to N-methyl-D-aspartate receptor (NMDAR)-mediated neuronal-ischemic injury, although their clinical significance in HTN requires further clarification. Objective: The aim of this study was to evaluate cross-sectional associations between arterial stiffness assessed by the cardio-ankle vascular index (CAVI), serum NR2 antibody levels, and cognitive performance assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in patients with essential HTN and controls. Methods: This single-center study included 175 adults aged 40–70 years: 128 patients with essential HTN and 47 controls. The median age was 58 [54; 66] years in the HTN group and 55 [47; 62] years in controls (p = 0.06). Men accounted for 52 patients (40.6%) in the HTN group and 14 participants (30.0%) in the control group (p = 0.22). Arterial stiffness was assessed using CAVI. Serum NR2 antibody levels were measured by enzyme-linked immunosorbent assay. Cognitive status was evaluated using MoCA and MMSE. Between-group comparisons, correlation analysis, and exploratory classification modeling were performed. Results: Patients with HTN had higher CAVI values than controls (8.3 [7.3; 9.4] vs. 7.3 [6.9; 7.9]; p = 0.001). Cognitive impairment was more frequent in hypertensive patients by both MoCA (52.3% vs. 27.7%; p = 0.003) and MMSE (48.7% vs. 28.3%; p = 0.01). NR2 antibody levels were higher in HTN (1.6 [1.15; 2.62] vs. 1.33 [1.02; 1.84] ng/mL; p = 0.03). CAVI inversely correlated with MoCA and MMSE scores. Conclusions: CAVI was higher in patients with HTN and showed modest inverse associations with cognitive scores. NR2 antibody levels were also higher in HTN; however, their relationship with cognitive impairment should be interpreted as exploratory and hypothesis-generating. Further longitudinal studies with neuroimaging are required to determine the clinical and prognostic significance of these findings.

28 October 2026 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
TST. A. Safronova
T. A. Safronova
SMSofia Eduardovna Mukhanova
Sofia Eduardovna Mukhanova
TVT. S. Vargina
T. S. Vargina
NDN. A. Dorokhov
N. A. Dorokhov
НДН. А. Дорохов
Н. А. Дорохов
Aim . To investigate the relationship between cognitive impairment (CI) and serum NR2 antibody (NR2-AB) levels in patients with controlled hypertension (HTN) of stage I-II. Material and methods. A single-centre study included 105 patients (75 with essential HTN and 30 controls) aged 40–70 years. Serum NR2-AB levels were measured by enzyme-linked immunosorbent assay (ELISA), with a threshold of 1.8 ng/mL. Cognitive status was assessed using the Montreal Cognitive Assessment (MoCA): normal ≥26 points, CI ≤25 points. All patients with HTN received combination antihypertensive therapy and had achieved target blood pressure levels at inclusion. Results . NR2-AB levels were significantly higher in HTN patients (2.93 [1.46; 4.13] ng/mL) than in controls (1.35 [1.02; 2.09] ng/mL; p=0.001). CI was detected 8 times more frequently in HTN patients compared with controls (52% vs 6.7%). A negative correlation was observed between NR2-AB levels and MoCA scores (r= 0.2; p=0.048). Furthermore, a significant association between the marker and the presence of cognitive impairment was found in the univariate regression analysis (odds ratio=1.21; 95% confidence interval: 1.027-1.42; p=0.022), suggesting that this neuronal injury marker is linked to cognitive decline. ROC analysis revealed that an NR2-AB cutoff of 1.73 ng/mL had discriminative capacity for CI (sensitivity 71%, specificity 50%). In the multivariable logistic regression analysis, age, body mass index, and the presence of HTN were significantly associated with CI; the association with NR2-AB levels was not statistically significant (p=0.143). Conclusion . In patients with controlled stage I-II HTN, serum NR2AB levels are significantly elevated even after achieving target blood pressure. Age, body mass index, and HTN were significantly associated with CI.